These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35967283)

  • 1. Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model.
    Zhang L; Zhu Y; Wei X; Chen X; Li Y; Zhu Y; Xia J; Huang Y; Huang Y; Wang J; Pang Z
    Acta Pharm Sin B; 2022 Aug; 12(8):3427-3447. PubMed ID: 35967283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells.
    Lu Y; Lian S; Ye Y; Yu T; Liang H; Cheng Y; Xie J; Zhu Y; Xie X; Yu S; Gao Y; Jia L
    Pharmacol Res; 2019 Jan; 139():535-549. PubMed ID: 30366102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-specific calcium nanoregulator suppressing the generation and circulation of circulating tumor cell clusters for enhanced anti-metastasis combinational chemotherapy.
    Li D; Wang Y; Li C; Wang Q; Sun B; Zhang H; He Z; Sun J
    Acta Pharm Sin B; 2021 Oct; 11(10):3262-3271. PubMed ID: 34729314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models.
    Papa AL; Jiang A; Korin N; Chen MB; Langan ET; Waterhouse A; Nash E; Caroff J; Graveline A; Vernet A; Mammoto A; Mammoto T; Jain A; Kamm RD; Gounis MJ; Ingber DE
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells.
    Ortiz-Otero N; Marshall JR; Lash BW; King MR
    Nanoscale Adv; 2020 Sep; 2(9):3942-3953. PubMed ID: 36132797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells.
    Mendonça L; Trindade A; Carvalho C; Correia J; Badenes M; Gigante J; Duarte A
    Clin Exp Metastasis; 2019 Aug; 36(4):365-380. PubMed ID: 31119445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules.
    Liu Y; Zhang Y; Ding Y; Zhuang R
    Crit Rev Oncol Hematol; 2021 Nov; 167():103502. PubMed ID: 34662726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.
    Hamilton G; Rath B
    Adv Exp Med Biol; 2017; 994():229-245. PubMed ID: 28560677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.
    Darga EP; Dolce EM; Fang F; Kidwell KM; Gersch CL; Kregel S; Thomas DG; Gill A; Brown ME; Gross S; Connelly M; Holinstat M; Cobain EF; Rae JM; Hayes DF; Paoletti C
    PLoS One; 2021; 16(11):e0260124. PubMed ID: 34780566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multipoint Costriking Nanodevice Eliminates Primary Tumor Cells and Associated-Circulating Tumor Cells for Enhancing Metastasis Inhibition and Therapeutic Effect on HCC.
    Mu W; Chu Q; Yang H; Guan L; Fu S; Gao T; Sang X; Zhang Z; Liang S; Liu Y; Zhang N
    Adv Sci (Weinh); 2022 Mar; 9(9):2101472. PubMed ID: 35356152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
    Bulfoni M; Gerratana L; Del Ben F; Marzinotto S; Sorrentino M; Turetta M; Scoles G; Toffoletto B; Isola M; Beltrami CA; Di Loreto C; Beltrami AP; Puglisi F; Cesselli D
    Breast Cancer Res; 2016 Mar; 18(1):30. PubMed ID: 26961140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
    Tawara K; Bolin C; Koncinsky J; Kadaba S; Covert H; Sutherland C; Bond L; Kronz J; Garbow JR; Jorcyk CL
    Breast Cancer Res; 2018 Jun; 20(1):53. PubMed ID: 29898744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of CTC Clusters in Breast Cancer Metastasis.
    Piñeiro R; Martínez-Pena I; López-López R
    Adv Exp Med Biol; 2020; 1220():93-115. PubMed ID: 32304082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.
    Koch C; Kuske A; Joosse SA; Yigit G; Sflomos G; Thaler S; Smit DJ; Werner S; Borgmann K; Gärtner S; Mossahebi Mohammadi P; Battista L; Cayrefourcq L; Altmüller J; Salinas-Riester G; Raithatha K; Zibat A; Goy Y; Ott L; Bartkowiak K; Tan TZ; Zhou Q; Speicher MR; Müller V; Gorges TM; Jücker M; Thiery JP; Brisken C; Riethdorf S; Alix-Panabières C; Pantel K
    EMBO Mol Med; 2020 Sep; 12(9):e11908. PubMed ID: 32667137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.
    Liu W; Vivian CJ; Brinker AE; Hampton KR; Lianidou E; Welch DR
    Cancer Microenviron; 2014 Dec; 7(3):117-31. PubMed ID: 24938990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic engineering of platelets to neutralize circulating tumor cells.
    Li J; Sharkey CC; Wun B; Liesveld JL; King MR
    J Control Release; 2016 Apr; 228():38-47. PubMed ID: 26921521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted downregulation of HIF-1α for restraining circulating tumor microemboli mediated metastasis.
    Du J; Wang C; Chen Y; Zhong L; Liu X; Xue L; Zhang Y; Li Y; Li X; Tang C; Su Z; Zhang C
    J Control Release; 2022 Mar; 343():457-468. PubMed ID: 35124127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.